Abstract: Skin is the human body's exterior integument. Human skin pigmentation varies from person to person, and skin types include dry, oily, and mixed. The human skin's diversity offers bacteria ...

Credit: Acrutis. Zoryve cream 0.05% is a once-daily, steroid-free cream for atopic dermatitis in patients aged 2 to 5 years. Zoryve cream 0.05% is expected to be available by the end of October 2025.

The US Food and Drug Administration (FDA) has approved Zoryve (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years. Once-daily ZORYVE ...

The once-daily, steroid-free cream can be used anywhere on the body for treatment and for any duration, according to Arcutis. FDA approved roflumilast cream 0.05% (Zoryve) for children aged 2–5 years ...

Body coverings such as hair and feathers have played a central role in evolution. They enabled warm-bloodedness by insulating the body, and were used for courtship, display, deterrence of enemies and, ...

Atopic dermatitis is a prevalent inflammatory skin condition among children and infants. Credit: Zhuravlev Andrey / Shutterstock. US-based biotechnology company Arcutis Biotherapeutics has enrolled ...

Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitis Atopic dermatitis impacts 9.6 million children ...

Arcutis Biotherapeutics has announced promising results from its Phase 3 INTEGUMENT-OLE study concerning the investigational ZORYVE cream for treating atopic dermatitis (AD). The long-term study ...

WESTLAKE VILLAGE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...